Wu Di, Xiong Liangfa
Department of Breast and Thyroid Surgery, The First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, P.R. China.
Oncol Lett. 2020 Mar;19(3):2539-2546. doi: 10.3892/ol.2020.11277. Epub 2020 Jan 24.
Efficacy of trastuzumab, carboplatin and docetaxel in human epidermal growth factor receptor-2 (HER-2)-positive breast cancer patients was investigated. A total of 180 HER-2-positive breast cancer patients admitted to The First People's Hospital of Yunnan Province were selected, of which 80 patients were treated with carboplatin and docetaxel and served as the control group (CG), and 100 patients were treated with trastuzumab, carboplatin and docetaxel and served as the research group (RG). Clinical efficacy, pathological efficacy, adverse reactions, inflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), cellular immune indexes of T-lymphocyte subsets (CD4, CD8, CD4/CD8), and the oxidative stress indexes superoxide dismutase (SOD) and myeloperoxidase (MPO) were observed before and after treatment and were compared between both groups. Patients were followed up for 5 years, and the 5-year disease-free survival (DFS), as well as the overall survival (OS) were compared. Clinical efficacy and pathological efficacy in the RG were significantly higher than those in the CG, and the incidence rate of adverse reactions had no significant difference between the two groups. There was no significant difference in inflammatory factors, cellular immune indexes and oxidative stress indexes between the two groups before treatment. After treatment, the levels of IL-6, TNF-α, CD8 and MPO in both groups were significantly reduced and were significantly lower in RG than those in CG. However, the levels of CD4, CD4/CD8 and SOD in both groups were significantly increased after treatment and were significantly higher in RG than those in CG. The 5-year DFS and OS of the RG were significantly higher than those of the CG. In conclusion, trastuzumab, carboplatin and docetaxel present high efficacy, safety, and 5-year DFS and OS in HER-2-positive breast cancer patients, and have good recovery effect on inflammation, immune response and oxidative stress.
研究了曲妥珠单抗、卡铂和多西他赛在人表皮生长因子受体2（HER-2）阳性乳腺癌患者中的疗效。选取云南省第一人民医院收治的180例HER-2阳性乳腺癌患者，其中80例患者接受卡铂和多西他赛治疗作为对照组（CG），100例患者接受曲妥珠单抗、卡铂和多西他赛治疗作为研究组（RG）。观察治疗前后的临床疗效、病理疗效、不良反应、炎症因子白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）、T淋巴细胞亚群的细胞免疫指标（CD4、CD8、CD4/CD8）以及氧化应激指标超氧化物歧化酶（SOD）和髓过氧化物酶（MPO），并比较两组间的差异。对患者进行5年随访，比较5年无病生存率（DFS）以及总生存率（OS）。RG的临床疗效和病理疗效显著高于CG，两组间不良反应发生率无显著差异。治疗前两组炎症因子、细胞免疫指标和氧化应激指标无显著差异。治疗后，两组IL-6、TNF-α、CD8和MPO水平均显著降低，且RG低于CG。然而，两组治疗后CD4、CD4/CD8和SOD水平均显著升高，且RG高于CG。RG的5年DFS和OS显著高于CG。综上所述，曲妥珠单抗、卡铂和多西他赛在HER-2阳性乳腺癌患者中具有高效、安全以及5年DFS和OS，并且对炎症、免疫反应和氧化应激具有良好的恢复作用。
